These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 29580635)

  • 41. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification .
    Gross P; Six I; Kamel S; Massy ZA
    Circ J; 2014; 78(10):2339-46. PubMed ID: 25077548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphate levels and cardiovascular disease in the general population.
    Foley RN
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1136-9. PubMed ID: 19423568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Con: Phosphate binders in chronic kidney disease.
    Kestenbaum B
    Nephrol Dial Transplant; 2016 Feb; 31(2):189-94. PubMed ID: 26681747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
    Gao Y; Wang G; Li Y; Lv C; Wang Z
    J Nephrol; 2019 Apr; 32(2):265-272. PubMed ID: 30588573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
    Dhillon-Jhattu S; Sprague SM
    Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
    Sigrist MK; Chiarelli G; Lim L; Levin A
    J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence of comparative effectiveness without evidence of effectiveness: the case of phosphate binders in CKD.
    Uhlig K
    Am J Kidney Dis; 2014 Jan; 63(1):13-5. PubMed ID: 24200463
    [No Abstract]   [Full Text] [Related]  

  • 56. Calcium-based phosphate binders and chronic kidney disease.
    Hiremath S; Akbari A
    Lancet; 2014 Jan; 383(9913):216. PubMed ID: 24439735
    [No Abstract]   [Full Text] [Related]  

  • 57. [Phosphate binders : What are the recent evidences ?].
    Bouajila IA; Martin PY; De Seigneux S
    Rev Med Suisse; 2017 Feb; 13(551):468-472. PubMed ID: 28714648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
    Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
    Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ACP Journal Club. Review: non-calcium-based phosphate binders reduce mortality compared with calcium-based binders in CKD.
    Parikh CR
    Ann Intern Med; 2013 Nov; 159(10):JC2. PubMed ID: 24247692
    [No Abstract]   [Full Text] [Related]  

  • 60. Most consumed processed foods by patients on hemodialysis: Alert for phosphate-containing additives and the phosphate-to-protein ratio.
    Watanabe MT; Araujo RM; Vogt BP; Barretti P; Caramori JCT
    Clin Nutr ESPEN; 2016 Aug; 14():37-41. PubMed ID: 28531397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.